Albumin & Creatinine Tests Market by Product (Analyzers, Cartridges (PoC, Tabletop), Dipsticks, Kits, Reagents), Type (Blood & Urine Creatinine, Urine Albumin, Glycated Albumin), Enduser (Hospital, Diagnostic & Research Labs) - Global Forecast to 2025

世界のアルブミン・クレアチニン検査市場予測:製品別、種類別、エンドユーザー別

◆タイトル:Albumin & Creatinine Tests Market by Product (Analyzers, Cartridges (PoC, Tabletop), Dipsticks, Kits, Reagents), Type (Blood & Urine Creatinine, Urine Albumin, Glycated Albumin), Enduser (Hospital, Diagnostic & Research Labs) - Global Forecast to 2025
◆商品コード:MD-7807
◆調査・発行会社:MarketsandMarkets
◆発行日:2021年1月14日
◆ページ数:155
◆レポート形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single User(1名様閲覧)USD4,950 ⇒換算¥519,750見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算¥698,250見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算¥855,750見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、レポートに記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はMarketsandMarketsの日本における正規販売代理店です。

【レポートの概要】

マーケッツアンドマーケッツ社は世界のアルブミン・クレアチニン検査市場規模が2020年987百万ドルから2025年2,103百万ドルまで、年平均16.3%成長すると予測しています。本調査レポートでは、アルブミン・クレアチニン検査の世界市場について調査・分析し、イントロダクション、調査手法、エグゼクティブサマリー、プレミアムインサイト、市場概要、製品別(ディップスティック・キット、分析装置、カートリッジ、試薬、その他)分析、種類別(尿検査、血尿・血清クレアチニン検査)分析、エンドユーザー別(病院・クリニック、診断研究所、研究所・施設)分析、地域別分析、競争状況、企業情報を掲載しています。
・イントロダクション
・調査手法
・エグゼクティブサマリー
・プレミアムインサイト
・市場概要
・アルブミン・クレアチニン検査の世界市場規模:製品別(ディップスティック・キット、分析装置、カートリッジ、試薬、その他)
・アルブミン・クレアチニン検査の世界市場規模:種類別(尿検査、血尿・血清クレアチニン検査)
・アルブミン・クレアチニン検査の世界市場規模:エンドユーザー別(病院・クリニック、診断研究所、研究所・施設)
・アルブミン・クレアチニン検査の世界市場規模:地域別
・競争状況
・企業情報

“The global albumin & creatinine tests market size is valued at an estimated USD 987 million in 2020 and is projected to reach USD 2,103 million by 2025, at a CAGR of 16.3% during the forecast period.”
The growth of the global albumin & creatinine tests market is driven by factors such as growing prevalence of kidney disorders, the rising adoption of POC diagnostics, and the increasing prevalence of chronic conditions. However, factors like unfavorable healthcare reforms in the US and the high cost of automated analyzers are hampering the growth of the albumin & creatinine tests market during the forecasted period.

“The dipstick & kits segment accounted for the highest growth rate in the albumin & creatinine tests market, by product, during the forecast period “
Based on product, the albumin & creatinine tests market is segmented into dipsticks & kits, analyzers, cartridges, and reagents & other consumables. In 2019, the dipsticks & kits segment accounted for the largest share in this market. The frequent purchase of these products compared to instruments like analyzers and cartridges and the increasing use of kit-based rapid techniques for albumin & creatinine tests drive market growth.

“Urine Tests segment accounted for the highest CAGR”
Based on type, the albumin & creatinine tests market is segmented into urine tests and blood & serum creatinine tests. In 2019, urine tests accounted for the largest share in this market. Factors such as the rapid growth in the diagnostics segment and the increasing demand for rapid and easy-to-use urine tests drive the growth of this segment.

“Asia Pacific: The fastest-growing region albumin & creatinine tests market”
The Asia Pacific albumin & creatinine tests market is estimated to grow at the highest CAGR, mainly due to the expansion of key market players in emerging Asian countries, increasing expenditure on life science and medical research in the region, and the increasing geriatric population and prevalence of chronic conditions in Asian countries such as India and China.

The primary interviews conducted for this report can be categorized as follows:
• By Company Type: Tier 1 – 20%, Tier 2 – 45%, and Tier 3 – 35%
• By Designation: C-level – 30%, D-level – 20%, and Others – 50%
• By Region: North America – 36%, Europe – 25%, Asia Pacific – 27%, Latin America – 9%, and Middle East and Africa – 3%.

List of companies profiled in the report:
• Thermo Fisher Scientific, Inc. (US)
• Roche Diagnostics (Switzerland)
• PromoCell GmbH (Germany)
• Abbott Laboratories (US)
• Siemens Healthineers (Germany)
• Danaher Corporation (US)
• Sysmex Corporation (Japan)
• Ortho Clinical Diagnostics (US)
• Randox Laboratories (UK)
• FUJIFILM Wako Pure Chemical Corporation (Japan)
• Abbexa Ltd. (UK)
• ACON Laboratories, Inc. (US)
• Arbor Assays Inc. (US)
• ARKRAY Global Business Inc. (Japan)
• Aviva Systems Biology (US)
• Axxora, LLC (UK)
• BioAssay Systems (US)
• Nova Biomedical (US)
• Quantimetrix Corporation (US)
• RayBiotech Inc. (US)
• Sekisui Diagnostics PEI Inc. (US)
• Teco Diagnostics (US)
• Tulip Diagnostics (India)
• ulti med Products GmbH (Germany)
• URIT Medical Electronic Co., Ltd. (China)

Research Coverage:
This report provides a detailed picture of the global albumin & creatinine tests market. It aims at estimating the size and future growth potential of the market across different segments, such as product, technique, application, end user, and region. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall albumin & creatinine tests market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide them with information on the key market drivers, restraints, opportunities, challenges, and trends.

【レポートの目次】

1 INTRODUCTION 23
1.1 OBJECTIVES OF THE STUDY 23
1.2 MARKET DEFINITION 23
FIGURE 1 INCLUSIONS & EXCLUSIONS 24
1.2.1 MARKETS COVERED 25
FIGURE 2 ALBUMIN & CREATININE TESTS MARKET SEGMENTATION 25
1.2.2 YEARS CONSIDERED FOR THE STUDY 26
1.3 CURRENCY 26
1.4 LIMITATIONS 26
1.5 STAKEHOLDERS 26
2 RESEARCH METHODOLOGY 27
2.1 RESEARCH DATA 27
FIGURE 3 RESEARCH DESIGN 27
2.1.1 SECONDARY DATA 28
2.1.1.1 Key data from secondary sources 28
2.1.2 PRIMARY DATA 29
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 30
2.2 MARKET SIZE ESTIMATION 30
2.2.1 BOTTOM-UP APPROACH 30
FIGURE 5 ALBUMIN & CREATININE TESTS MARKET: BOTTOM-UP APPROACH 31
2.2.2 TOP-DOWN APPROACH 31
FIGURE 6 ALBUMIN & CREATININE TESTS MARKET: TOP-DOWN APPROACH 31
2.3 MARKET BREAKDOWN & DATA TRIANGULATION 32
FIGURE 7 DATA TRIANGULATION METHODOLOGY 32
2.4 ASSUMPTIONS FOR THE STUDY 33
3 EXECUTIVE SUMMARY 34
FIGURE 8 ALBUMIN & CREATININE TESTS MARKET, BY PRODUCT,
2020 VS. 2025 (USD MILLION) 34
FIGURE 9 ALBUMIN & CREATININE TESTS MARKET, BY TYPE,
2020 VS. 2025 (USD MILLION) 35
FIGURE 10 ALBUMIN & CREATININE TESTS MARKET, BY END USER,
2020 VS. 2025 (USD MILLION) 35
FIGURE 11 ALBUMIN & CREATININE TESTS MARKET, BY REGION,
2020 VS. 2025 (USD MILLION) 36

4 PREMIUM INSIGHTS 37
4.1 ALBUMIN & CREATININE TESTS MARKET OVERVIEW 37
FIGURE 12 RISING ADOPTION OF POC PRODUCTS TO DRIVE MARKET GROWTH 37
4.2 ALBUMIN & CREATININE TESTS MARKET, BY CARTRIDGE TYPE,
2020 VS. 2025 (USD MILLION) 38
FIGURE 13 POC ANALYZER CARTRIDGES SEGMENT TO COMMAND THE LARGEST MARKET SHARE IN 2019 38
4.3 URINE TESTS MARKET, BY TYPE, 2020 VS. 2025 38
FIGURE 14 URINE ALBUMIN TESTS TO HOLD THE LARGEST MARKET SHARE 38
4.4 ALBUMIN & CREATININE TESTS MARKET, BY REGION, 2020 VS. 2025 39
FIGURE 15 ASIA PACIFIC MARKET TO GROW AT THE HIGHEST CAGR DURING THE FORECAST PERIOD 39
5 MARKET OVERVIEW 40
5.1 INTRODUCTION 40
5.2 MARKET DYNAMICS 40
FIGURE 16 ALBUMIN & CREATININE TESTS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 40
5.2.1 DRIVERS 41
5.2.1.1 Rising prevalence of kidney disorders 41
5.2.1.2 Increasing adoption of point-of-care (POC) diagnostics 41
5.2.1.3 Growing global prevalence of chronic conditions leading
to kidney diseases 41
5.2.2 RESTRAINTS 42
5.2.2.1 Unfavorable healthcare reforms in the US 42
5.2.3 OPPORTUNITIES 42
5.2.3.1 Integrated and automated systems for overall urine analysis 42
5.2.3.2 Emerging economies to provide significant opportunities 42
5.2.4 CHALLENGES 43
5.2.4.1 High cost of automated analyzers 43
5.2.4.2 High degree of consolidation acts as an entry barrier for new entrants 43
5.3 IMPACT OF COVID-19 ON THE ALBUMIN & CREATININE TESTS MARKET 44
5.4 ECOSYSTEM ANALYSIS 44
5.5 VALUE CHAIN ANALYSIS 45
FIGURE 17 VALUE CHAIN ANALYSIS OF THE ALBUMIN & CREATININE TESTS MARKET 45
FIGURE 18 RESTRAINTS IN THE VALUE CHAIN FOR POC DIAGNOSTICS, BY STAGE 46
5.6 SUPPLY CHAIN ANALYSIS 46
FIGURE 19 SUPPLY CHAIN ANALYSIS OF THE ALBUMIN & CREATININE TESTS MARKET 47
5.7 PESTLE ANALYSIS 48
FIGURE 20 PESTLE ANALYSIS OF THE ALBUMIN & CREATININE TESTS MARKET 48

6 ALBUMIN & CREATININE TESTS MARKET, BY PRODUCT 49
6.1 INTRODUCTION 50
TABLE 1 AVERAGE SELLING PRICES OF PRODUCTS (USD) 50
TABLE 2 ALBUMIN & CREATININE TESTS MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 50
6.2 DIPSTICKS & KITS 51
6.2.1 COST-EFFECTIVENESS AND EASE OF USE TO DRIVE MARKET GROWTH 51
TABLE 3 DIPSTICKS & KITS MARKET, BY REGION, 2018–2025 (USD MILLION) 51
6.3 ANALYZERS 52
6.3.1 ADOPTION OF POC ANALYZERS HAS INCREASED IN RECENT YEARS 52
TABLE 4 ANALYZERS MARKET, BY REGION, 2018–2025 (USD MILLION) 52
6.4 CARTRIDGES 53
TABLE 5 CARTRIDGES MARKET, BY REGION, 2018–2025 (USD MILLION) 53
TABLE 6 CARTRIDGES MARKET, BY TYPE, 2018–2025 (USD MILLION) 53
6.4.1 POC ANALYZER CARTRIDGES 54
6.4.1.1 Increasing adoption of POC technologies to drive market growth 54
TABLE 7 POC ANALYZER CARTRIDGES MARKET, BY REGION,
2018–2025 (USD MILLION) 54
6.4.2 TABLE-TOP ANALYZER CARTRIDGES 54
6.4.2.1 Table-top analyzers and cartridges are used in hospitals, labs, and research 54
TABLE 8 TABLE-TOP ANALYZER CARTRIDGES MARKET, BY REGION,
2018–2025 (USD MILLION) 55
6.5 REAGENTS & OTHER CONSUMABLES 55
6.5.1 INCREASING USE OF CONTROLS AND CALIBRATORS TO DRIVE MARKET GROWTH 55
TABLE 9 REAGENTS & OTHER CONSUMABLES MARKET, BY REGION,
2018–2025 (USD MILLION) 56
7 ALBUMIN & CREATININE TESTS MARKET, BY TYPE 57
7.1 INTRODUCTION 58
TABLE 10 ALBUMIN & CREATININE TESTS MARKET, BY TYPE,
2018–2025 (USD MILLION) 58
7.2 URINE TESTS 58
TABLE 11 URINE TESTS MARKET, BY TYPE, 2018–2025 (USD MILLION) 59
TABLE 12 URINE TESTS MARKET, BY REGION, 2018–2025 (USD MILLION) 59
7.2.1 URINE ALBUMIN TESTS 59
7.2.1.1 Increasing prevalence of hypertension to drive market growth 59
TABLE 13 URINE ALBUMIN TESTS MARKET, BY REGION, 2018–2025 (USD MILLION) 60
7.2.2 URINE CREATININE TESTS 60
7.2.2.1 Increasing prevalence of drug nephrotoxicity to drive market growth 60
TABLE 14 URINE CREATININE TESTS MARKET, BY REGION, 2018–2025 (USD MILLION) 61
7.2.3 GLYCATED ALBUMIN TESTS 61
7.2.3.1 Increasing prevalence of diabetes to drive market growth 61
TABLE 15 GLYCATED ALBUMIN TESTS MARKET, BY REGION,
2018–2025 (USD MILLION) 61
7.3 BLOOD & SERUM CREATININE TESTS 62
7.3.1 INCREASING PREVALENCE OF CHRONIC CONDITIONS TO DRIVE MARKET GROWTH 62
TABLE 16 BLOOD & SERUM CREATININE TESTS MARKET, BY REGION,
2018–2025 (USD MILLION) 62
8 ALBUMIN & CREATININE TESTS MARKET, BY END USER 63
8.1 INTRODUCTION 64
TABLE 17 ALBUMIN & CREATININE TESTS MARKET, BY END USER,
2018–2025 (USD MILLION) 64
8.2 HOSPITALS & CLINICS 64
8.2.1 RISING NUMBER OF HOSPITALS TO DRIVE MARKET GROWTH 64
TABLE 18 ALBUMIN & CREATININE TESTS MARKET FOR HOSPITALS & CLINICS,
BY REGION, 2018–2025 (USD MILLION) 65
8.3 DIAGNOSTIC LABORATORIES 65
8.3.1 INCREASING OUTSOURCING BY HOSPITALS IS SUPPORTING THE GROWTH OF THIS END-USER SEGMENT 65
TABLE 19 ALBUMIN & CREATININE TESTS MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2018–2025 (USD MILLION) 66
8.4 RESEARCH LABORATORIES & INSTITUTES 66
8.4.1 INCREASING INVESTMENTS IN RESEARCH IS THE MAJOR FACTOR CONTRIBUTING TO MARKET GROWTH 66
TABLE 20 ALBUMIN & CREATININE TESTS MARKET FOR RESEARCH LABORATORIES & INSTITUTES, BY REGION, 2018–2025 (USD MILLION) 67
9 ALBUMIN & CREATININE TESTS MARKET, BY REGION 68
9.1 INTRODUCTION 69
TABLE 21 ALBUMIN & CREATININE TESTS MARKET, BY REGION,
2018–2025 (USD MILLION) 69
9.2 NORTH AMERICA 69
FIGURE 21 NORTH AMERICA: ALBUMIN & CREATININE TESTS MARKET SNAPSHOT 70
TABLE 22 NORTH AMERICA: ALBUMIN & CREATININE TESTS MARKET, BY COUNTRY, 2018–2025 (USD MILLION) 70
TABLE 23 NORTH AMERICA: ALBUMIN & CREATININE TESTS MARKET, BY PRODUCT, 2018–2025 (USD MILLION) 71
TABLE 24 NORTH AMERICA: ALBUMIN & CREATININE TESTS MARKET, BY TYPE,
2018–2025 (USD MILLION) 71
TABLE 25 NORTH AMERICA: ALBUMIN & CREATININE TESTS MARKET, BY END USER, 2018–2025 (USD MILLION) 71
9.2.1 US 72
9.2.1.1 Increasing geriatric population to drive market growth in the US 72
TABLE 26 US: ALBUMIN & CREATININE TESTS MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 72
TABLE 27 US: ALBUMIN & CREATININE TEST CARTRIDGES MARKET, BY TYPE,
2018–2025 (USD MILLION) 73
TABLE 28 US: ALBUMIN & CREATININE TESTS MARKET, BY TYPE,
2018–2025 (USD MILLION) 73
TABLE 29 US: URINE TESTS MARKET, BY TYPE, 2018–2025 (USD MILLION) 73
TABLE 30 US: ALBUMIN & CREATININE TESTS MARKET, BY END USER,
2018–2025 (USD MILLION) 74
9.2.2 CANADA 74
9.2.2.1 Rising prevalence of diabetes to drive market growth 74
TABLE 31 CANADA: INCIDENCE OF DIABETES, 2019 VS. 2029 74
TABLE 32 CANADA: ALBUMIN & CREATININE TESTS MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 75
TABLE 33 CANADA: ALBUMIN & CREATININE TEST CARTRIDGES MARKET, BY TYPE, 2018–2025 (USD MILLION) 75
TABLE 34 CANADA: ALBUMIN & CREATININE TESTS MARKET, BY TYPE,
2018–2025 (USD MILLION) 75
TABLE 35 CANADA: URINE TESTS MARKET, BY TYPE, 2018–2025 (USD MILLION) 76
TABLE 36 CANADA: ALBUMIN & CREATININE TESTS MARKET, BY END USER,
2018–2025 (USD MILLION) 76
9.3 EUROPE 76
TABLE 37 EUROPE: PREVALENCE OF DIABETES (20–79 YEARS), 2019 VS. 2045 76
TABLE 38 EUROPE: ALBUMIN & CREATININE TESTS MARKET, BY COUNTRY,
2018–2025 (USD MILLION) 77
TABLE 39 EUROPE: ALBUMIN & CREATININE TESTS MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 77
TABLE 40 EUROPE: ALBUMIN & CREATININE TESTS MARKET, BY TYPE,
2018–2025 (USD MILLION) 78
TABLE 41 EUROPE: ALBUMIN & CREATININE TESTS MARKET, BY END USER,
2018–2025 (USD MILLION) 78
9.3.1 UK 78
9.3.1.1 Rising incidence of chronic kidney disorders to drive market growth 78
TABLE 42 UK: ALBUMIN & CREATININE TESTS MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 79
TABLE 43 UK: ALBUMIN & CREATININE TEST CARTRIDGES MARKET, BY TYPE,
2018–2025 (USD MILLION) 79
TABLE 44 UK: ALBUMIN & CREATININE TESTS MARKET, BY TYPE,
2018–2025 (USD MILLION) 79
TABLE 45 UK: URINE TESTS MARKET, BY TYPE, 2018–2025 (USD MILLION) 80
TABLE 46 UK: ALBUMIN & CREATININE TESTS MARKET, BY END USER,
2018–2025 (USD MILLION) 80
9.3.2 GERMANY 80
9.3.2.1 Increasing healthcare expenditure to drive market growth 80
TABLE 47 GERMANY: ALBUMIN & CREATININE TESTS MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 81
TABLE 48 GERMANY: ALBUMIN & CREATININE TEST CARTRIDGES MARKET,
BY TYPE, 2018–2025 (USD MILLION) 81
TABLE 49 GERMANY: ALBUMIN & CREATININE TESTS MARKET, BY TYPE,
2018–2025 (USD MILLION) 81
TABLE 50 GERMANY: URINE TESTS MARKET, BY TYPE, 2018–2025 (USD MILLION) 82
TABLE 51 GERMANY: ALBUMIN & CREATININE TESTS MARKET, BY END USER,
2018–2025 (USD MILLION) 82
9.3.3 FRANCE 82
9.3.3.1 Rising R&D expenditure to drive market growth 82
TABLE 52 FRANCE: ALBUMIN & CREATININE TESTS MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 83
TABLE 53 FRANCE: ALBUMIN & CREATININE TEST CARTRIDGES MARKET, BY TYPE, 2018–2025 (USD MILLION) 83
TABLE 54 FRANCE: ALBUMIN & CREATININE TESTS MARKET, BY TYPE,
2018–2025 (USD MILLION) 83
TABLE 55 FRANCE: URINE TESTS MARKET, BY TYPE, 2018–2025 (USD MILLION) 84
TABLE 56 FRANCE: ALBUMIN & CREATININE TESTS MARKET, BY END USER,
2018–2025 (USD MILLION) 84
9.3.4 ITALY 84
9.3.4.1 Large geriatric population to drive the growth of the albumin & creatinine tests market in Italy 84
TABLE 57 ITALY: ALBUMIN & CREATININE TESTS MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 85
TABLE 58 ITALY: ALBUMIN & CREATININE TEST CARTRIDGES MARKET, BY TYPE,
2018–2025 (USD MILLION) 85
TABLE 59 ITALY: ALBUMIN & CREATININE TESTS MARKET, BY TYPE,
2018–2025 (USD MILLION) 85
TABLE 60 ITALY: URINE TESTS MARKET, BY TYPE, 2018–2025 (USD MILLION) 86
TABLE 61 ITALY: ALBUMIN & CREATININE TESTS MARKET, BY END USER,
2018–2025 (USD MILLION) 86
9.3.5 SPAIN 86
9.3.5.1 Rising prevalence of CKD in Spain to drive market growth 86
TABLE 62 SPAIN: ALBUMIN & CREATININE TESTS MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 87
TABLE 63 SPAIN: ALBUMIN & CREATININE TEST CARTRIDGES MARKET, BY TYPE,
2018–2025 (USD MILLION) 87
TABLE 64 SPAIN: ALBUMIN & CREATININE TESTS MARKET, BY TYPE,
2018–2025 (USD MILLION) 87
TABLE 65 SPAIN: URINE TESTS MARKET, BY TYPE, 2018–2025 (USD MILLION) 88
TABLE 66 SPAIN: ALBUMIN & CREATININE TESTS MARKET, BY END USER,
2018–2025 (USD MILLION) 88
9.3.6 RUSSIA 88
9.3.6.1 Government focus on increasing diabetes awareness will favor market growth in Russia 88
TABLE 67 RUSSIA: ALBUMIN & CREATININE TESTS MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 89
TABLE 68 RUSSIA: ALBUMIN & CREATININE TEST CARTRIDGES MARKET, BY TYPE, 2018–2025 (USD MILLION) 89
TABLE 69 RUSSIA: ALBUMIN & CREATININE TESTS MARKET, BY TYPE,
2018–2025 (USD MILLION) 89
TABLE 70 RUSSIA: URINE TESTS MARKET, BY TYPE, 2018–2025 (USD MILLION) 90
TABLE 71 RUSSIA: ALBUMIN & CREATININE TESTS MARKET, BY END USER,
2018–2025 (USD MILLION) 90
9.3.7 REST OF EUROPE 90
TABLE 72 ROE: ALBUMIN & CREATININE TESTS MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 91
TABLE 73 ROE: ALBUMIN & CREATININE TEST CARTRIDGES MARKET, BY TYPE,
2018–2025 (USD MILLION) 91
TABLE 74 ROE: ALBUMIN & CREATININE TESTS MARKET, BY TYPE,
2018–2025 (USD MILLION) 91
TABLE 75 ROE: URINE TESTS MARKET, BY TYPE, 2018–2025 (USD MILLION) 92
TABLE 76 ROE: ALBUMIN & CREATININE TESTS MARKET, BY END USER,
2018–2025 (USD MILLION) 92
9.4 ASIA PACIFIC 92
FIGURE 22 APAC: ALBUMIN & CREATININE TESTS MARKET SNAPSHOT 93
TABLE 77 APAC: ALBUMIN & CREATININE TESTS MARKET, BY COUNTRY,
2018–2025 (USD MILLION) 94
TABLE 78 APAC: ALBUMIN & CREATININE TESTS MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 94
TABLE 79 APAC: ALBUMIN & CREATININE TESTS MARKET, BY TYPE,
2018–2025 (USD MILLION) 94
TABLE 80 APAC: ALBUMIN & CREATININE TESTS MARKET, BY END USER,
2018–2025 (USD MILLION) 95
9.4.1 CHINA 95
9.4.1.1 China accounts for the largest share of the APAC market 95
TABLE 81 CHINA: ALBUMIN & CREATININE TESTS MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 96
TABLE 82 CHINA: ALBUMIN & CREATININE TEST CARTRIDGES MARKET, BY TYPE,
2018–2025 (USD MILLION) 96
TABLE 83 CHINA: ALBUMIN & CREATININE TESTS MARKET, BY TYPE,
2018–2025 (USD MILLION) 96
TABLE 84 CHINA: URINE TESTS MARKET, BY TYPE, 2018–2025 (USD MILLION) 97
TABLE 85 CHINA: ALBUMIN & CREATININE TESTS MARKET, BY END USER,
2018–2025 (USD MILLION) 97
9.4.2 JAPAN 97
9.4.2.1 Favorable regulatory framework to drive market growth 97
TABLE 86 JAPAN: ALBUMIN & CREATININE TESTS MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 98
TABLE 87 JAPAN: ALBUMIN & CREATININE TEST CARTRIDGES MARKET, BY TYPE,
2018–2025 (USD MILLION) 98
TABLE 88 JAPAN: ALBUMIN & CREATININE TESTS MARKET, BY TYPE,
2018–2025 (USD MILLION) 99
TABLE 89 JAPAN: URINE TESTS MARKET, BY TYPE, 2018–2025 (USD MILLION) 99
TABLE 90 JAPAN: ALBUMIN & CREATININE TESTS MARKET, BY END USER,
2018–2025 (USD MILLION) 99
9.4.3 AUSTRALIA 100
9.4.3.1 Increasing incidence of diabetes is driving market growth 100
TABLE 91 AUSTRALIA: ALBUMIN & CREATININE TESTS MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 100
TABLE 92 AUSTRALIA: ALBUMIN & CREATININE TEST CARTRIDGES MARKET, BY TYPE, 2018–2025 (USD MILLION) 100
TABLE 93 AUSTRALIA: ALBUMIN & CREATININE TESTS MARKET, BY TYPE,
2018–2025 (USD MILLION) 101
TABLE 94 AUSTRALIA: URINE TESTS MARKET, BY TYPE, 2018–2025 (USD MILLION) 101
TABLE 95 AUSTRALIA: ALBUMIN & CREATININE TESTS MARKET, BY END USER,
2018–2025 (USD MILLION) 101
9.4.4 SOUTH KOREA 102
9.4.4.1 Rising geriatric population to drive market growth 102
TABLE 96 SOUTH KOREA: ALBUMIN & CREATININE TESTS MARKET, BY PRODUCT, 2018–2025 (USD MILLION) 102
TABLE 97 SOUTH KOREA: ALBUMIN & CREATININE TEST CARTRIDGES MARKET,
BY TYPE, 2018–2025 (USD MILLION) 102
TABLE 98 SOUTH KOREA: ALBUMIN & CREATININE TESTS MARKET, BY TYPE,
2018–2025 (USD MILLION) 103
TABLE 99 SOUTH KOREA: URINE TESTS MARKET, BY TYPE, 2018–2025 (USD MILLION) 103
TABLE 100 SOUTH KOREA: ALBUMIN & CREATININE TESTS MARKET, BY END USER, 2018–2025 (USD MILLION) 103
9.4.5 REST OF ASIA PACIFIC 104
TABLE 101 ROAPAC: ALBUMIN & CREATININE TESTS MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 104
TABLE 102 ROAPAC: ALBUMIN & CREATININE TEST CARTRIDGES MARKET, BY TYPE, 2018–2025 (USD MILLION) 104
TABLE 103 ROAPAC: ALBUMIN & CREATININE TESTS MARKET, BY TYPE,
2018–2025 (USD MILLION) 105
TABLE 104 ROAPAC: URINE TESTS MARKET, BY TYPE, 2018–2025 (USD MILLION) 105
TABLE 105 ROAPAC: ALBUMIN & CREATININE TESTS MARKET, BY END USER,
2018–2025 (USD MILLION) 105
9.5 LATIN AMERICA 106
TABLE 106 LATIN AMERICA: ALBUMIN & CREATININE TESTS MARKET, BY COUNTRY, 2018–2025 (USD MILLION) 106
TABLE 107 LATIN AMERICA: ALBUMIN & CREATININE TESTS MARKET, BY PRODUCT, 2018–2025 (USD MILLION) 107
TABLE 108 LATIN AMERICA: ALBUMIN & CREATININE TESTS MARKET, BY TYPE,
2018–2025 (USD MILLION) 107
TABLE 109 LATIN AMERICA: ALBUMIN & CREATININE TESTS MARKET, BY END USER, 2018–2025 (USD MILLION) 107
9.5.1 BRAZIL 108
9.5.1.1 High prevalence of chronic conditions to promote market growth 108
TABLE 110 BRAZIL: ALBUMIN & CREATININE TESTS MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 108
TABLE 111 BRAZIL: ALBUMIN & CREATININE TEST CARTRIDGES MARKET, BY TYPE, 2018–2025 (USD MILLION) 108
TABLE 112 BRAZIL: ALBUMIN & CREATININE TESTS MARKET, BY TYPE,
2018–2025 (USD MILLION) 109
TABLE 113 BRAZIL: URINE TESTS MARKET, BY TYPE, 2018–2025 (USD MILLION) 109
TABLE 114 BRAZIL: ALBUMIN & CREATININE TESTS MARKET, BY END USER,
2018–2025 (USD MILLION) 109
9.5.2 MEXICO 110
9.5.2.1 Rising prevalence of diabetes to drive market growth in Mexico 110
TABLE 115 MEXICO: ALBUMIN & CREATININE TESTS MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 110
TABLE 116 MEXICO: ALBUMIN & CREATININE TEST CARTRIDGES MARKET, BY TYPE, 2018–2025 (USD MILLION) 110
TABLE 117 MEXICO: ALBUMIN & CREATININE TESTS MARKET, BY TYPE,
2018–2025 (USD MILLION) 111
TABLE 118 MEXICO: URINE TESTS MARKET, BY TYPE, 2018–2025 (USD MILLION) 111
TABLE 119 MEXICO: ALBUMIN & CREATININE TESTS MARKET, BY END USER,
2018–2025 (USD MILLION) 111
9.5.3 REST OF LATIN AMERICA 112
TABLE 120 ROLATAM: ALBUMIN & CREATININE TESTS MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 112
TABLE 121 ROLATAM: ALBUMIN & CREATININE TEST CARTRIDGES MARKET, BY TYPE, 2018–2025 (USD MILLION) 112
TABLE 122 ROLATAM: ALBUMIN & CREATININE TESTS MARKET, BY TYPE,
2018–2025 (USD MILLION) 112
TABLE 123 ROLATAM: URINE TESTS MARKET, BY TYPE, 2018–2025 (USD MILLION) 113
TABLE 124 ROLATAM: ALBUMIN & CREATININE TESTS MARKET, BY END USER,
2018–2025 (USD MILLION) 113
9.6 MIDDLE EAST AND AFRICA 113
9.6.1 INCREASING HEALTHCARE EXPENDITURE TO DRIVE MARKET GROWTH IN THE MIDDLE EAST AND AFRICA 113
TABLE 125 MEA: ALBUMIN & CREATININE TESTS MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 114
TABLE 126 MEA: ALBUMIN & CREATININE TESTS MARKET, BY TYPE,
2018–2025 (USD MILLION) 114
TABLE 127 MEA: ALBUMIN & CREATININE TESTS MARKET, BY END USER,
2018–2025 (USD MILLION) 114
10 COMPETITIVE LANDSCAPE 115
10.1 OVERVIEW 115
FIGURE 23 KEY DEVELOPMENTS IN THE ALBUMIN & CREATININE TESTS MARKET (JANUARY 2017–NOVEMBER 2020) 115
10.2 ALBUMIN & CREATININE TESTS MARKET SHARE ANALYSIS 116
FIGURE 24 ALBUMIN & CREATININE TESTS MARKET SHARE ANALYSIS, BY KEY PLAYER, 2019 116
10.3 COMPANY EVALUATION QUADRANT 116
10.3.1 DEFINITION AND METHODOLOGY 116
10.3.2 VENDOR DIVE OVERVIEW 116
10.3.2.1 Stars 116
10.3.2.2 Emerging leaders 117
10.3.2.3 Pervasive 117
10.3.2.4 Participants 117

FIGURE 25 ALBUMIN & CREATININE TESTS MARKET: COMPETITIVE LEADERSHIP MAPPING, 2019 118
10.4 COMPANY EVALUATION MATRIX FOR START-UPS (2019) 119
10.4.1 PROGRESSIVE COMPANIES 119
10.4.2 RESPONSIVE COMPANIES 119
10.4.3 STARTING BLOCKS 119
10.4.4 DYNAMIC COMPANIES 119
FIGURE 26 ALBUMIN & CREATININE TESTS MARKET: COMPETITIVE LEADERSHIP MAPPING FOR START-UPS, 2019 120
10.5 COMPETITIVE SCENARIO 121
10.5.1 PRODUCT LAUNCHES & REGULATORY APPROVALS 121
TABLE 128 PRODUCT LAUNCHES & REGULATORY APPROVALS (JANUARY 2017–NOVEMBER 2020) 121
10.5.2 PARTNERSHIPS & AGREEMENTS 121
TABLE 129 PARTNERSHIPS & AGREEMENTS (JANUARY 2017–NOVEMBER 2020) 121
10.5.3 ACQUISITIONS 122
TABLE 130 ACQUISITIONS (JANUARY 2017–NOVEMBER 2020) 122
10.5.4 EXPANSIONS 122
TABLE 131 EXPANSIONS (JANUARY 2017–NOVEMBER 2020) 122
11 COMPANY PROFILES 123
11.1 KEY PLAYERS 123
(Business Overview, Products Offered, Recent Developments, MnM View)*
11.1.1 ABBOTT LABORATORIES 123
FIGURE 27 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2019) 123
11.1.2 ROCHE DIAGNOSTICS (A DIVISION OF F. HOFFMAN-LA ROCHE AG) 125
FIGURE 28 F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT (2019) 125
11.1.3 SIEMENS HEALTHINEERS AG 127
FIGURE 29 SIEMENS HEALTHINEERS: COMPANY SNAPSHOT (2019) 127
11.1.4 DANAHER CORPORATION 129
FIGURE 30 DANAHER CORPORATION: COMPANY SNAPSHOT (2019) 129
11.1.5 THERMO FISHER SCIENTIFIC, INC. 131
FIGURE 31 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2019) 131
11.1.6 SYSMEX CORPORATION 133
FIGURE 32 SYSMEX CORPORATION: COMPANY SNAPSHOT (2019) 133
11.1.7 ORTHO CLINICAL DIAGNOSTICS 135
11.1.8 PROMOCELL GMBH 136
11.1.9 RANDOX LABORATORIES 137
11.1.10 FUJIFILM WAKO PURE CHEMICAL CORPORATION 138
11.2 OTHER PLAYERS 139
11.2.1 ABBEXA LTD. 139
11.2.2 ACON LABORATORIES, INC. 140
11.2.3 ARBOR ASSAYS, INC. 141
11.2.4 ARKRAY GLOBAL BUSINESS, INC. 142
11.2.5 AVIVA SYSTEMS BIOLOGY 143
11.2.6 AXXORA, LLC 144
11.2.7 BIOASSAY SYSTEMS 145
11.2.8 NOVA BIOMEDICAL CORPORATION 146
11.2.9 QUANTIMETRIX CORPORATION 147
11.2.10 RAYBIOTECH, INC. 148
11.2.11 SEKISUI DIAGNOSTICS PEI INC. 149
11.2.12 TECO DIAGNOSTICS 150
11.2.13 TULIP DIAGNOSTICS LTD. 151
11.2.14 ULTI MED PRODUCTS GMBH 152
11.2.15 URIT MEDICAL ELECTRONIC CO., LTD. 153
*Business Overview, Products Offered, Recent Developments, MnM View might not be captured in case of unlisted companies.
12 APPENDIX 154
12.1 DISCUSSION GUIDE 154
12.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 156
12.3 AVAILABLE CUSTOMIZATIONS 158
12.4 RELATED REPORTS 158
12.5 AUTHOR DETAILS 159



【免責事項】
※当レポート上の情報/データは調査会社が信頼できると判断した情報源から入手したものに基づき作成しましたが、その正確性・完全性を保証するものではありません。当レポートに記載された情報/データ/見解/仮説などは作成時点又は発行時点における調査会社の判断であり、その後の状況変化に応じて変更される場合があります。当レポート上の情報/データに基づいたお客様の意思決定又は実行による結果について、調査会社/発行会社/販売会社H&Iグローバルリサーチはその責を負いかねますのでご了承ください。英文資料の紹介ページにおける日本語題名/概要/目次はH&Iグローバルリサーチが翻訳した内容であり、翻訳の正確性・完全性を保証するものではありません。

[世界のアルブミン・クレアチニン検査市場予測:製品別、種類別、エンドユーザー別]についてメールでお問い合わせはこちら


◆H&Iグローバルリサーチ株式会社のお客様(例)◆